CE Disclosures and Faculty Information

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.
  
  OVERVIEW OF ACTIVITY
  Breast cancer remains the most frequently diagnosed cancer in women, and in 2017 in the United States alone the disease will culminate in an estimated 255,180 new cases and 41,070 deaths. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only about 5% of women have identifiable distant metastases with primary diagnosis. Consequently, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.
  
  The current clinical management of breast cancer is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease (micro- or macroscopic) with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these approaches. The indication and/or utility of these available local and systemic treatment options is largely based on a number of prognostic and predictive risk factors present in the patient or the tumor at the time of diagnosis. In fact, as the field of oncology is challenged to improve the precision with which it therapeutically targets malignant cells, biomarker-driven treatment algorithms have become the “norm” for many tumor types, particularly breast cancer.
  
  Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making breast cancer management decisions in the face of this dynamic environment. But despite the existence of these tools, many areas of controversy persist within academic and community settings. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies in the management of breast cancer, which in turn facilitates optimal patient care.
  
  LEARNING OBJECTIVES

  • Appraise recently published clinical research data and adapt current breast cancer diagnostic and management approaches on the basis of practice-changing findings.
  • Appreciate the similarities and differences between existing genomic assays, and use this information to select the appropriate platform to assess risk and individualize therapy for patients with invasive and noninvasive early breast cancer.
  • Develop an evidence-based algorithm for the initial and long-term treatment of localized hormone receptor-positive pre- and postmenopausal breast cancer.
  • Individualize the selection of evidence-based neoadjuvant and adjuvant chemobiologic regimens for patients with HER2-positive breast cancer.
  • Develop an understanding of the mechanisms of action, available research data and ongoing trials of approved and investigational CDK4/6 inhibitors and other novel therapies under investigation in the management of advanced breast cancer.
  • Consider clinical data and patient preferences in the selection and sequencing of available therapeutic agents for patients with newly diagnosed and metastatic triple-negative breast cancer.
  • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials investigating novel therapeutic agents and strategies.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for continuing medical education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of slide and video components.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Kimberly L Blackwell, MD
  Professor of Medicine
  Director, Breast Cancer Program
  Duke Cancer Institute
  Durham, North Carolina
  
  Advisory Committee: Advaxis Inc, Bayer HealthCare Pharmaceuticals, Eisai Inc, MacroGenics Inc, Merck, Novartis, Pfizer Inc, Pierian Biosciences, Syndax Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Coherus Biosciences, G1 Therapeutics, Genentech BioOncology, Lilly, Puma Biotechnology Inc, Sandoz, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Genentech BioOncology, Novartis, Pfizer Inc.
  
  Karen A Gelmon, MD
  Professor, Medicine
  Head, Division of Medical Oncology
  University of British Columbia
  Medical Oncologist, BC Cancer Agency
  Vancouver Cancer Centre
  Vancouver, Canada
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Lilly, Merck, Novartis, Pfizer Inc.
  
  Ian E Krop, MD, PhD
  Director of Clinical Research
  Breast Oncology Center
  Dana-Farber Cancer Institute
  Assistant Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Genentech BioOncology, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Roche Laboratories Inc.
  
  Kathy D Miller, MD
  Co-Director, IU Simon Cancer Center Breast Cancer Program
  Ballvé-Lantero Scholar in Oncology
  Professor of Medicine
  Division of Hematology/Oncology
  Indiana University Melvin and Bren Simon Cancer Center 
  Indianapolis, Indiana
  
  Contracted Research: Astellas Pharma Global Development Inc, Genentech BioOncology, Medivation Inc, a Pfizer Company, Merrimack Pharmaceuticals Inc, Novartis, Pfizer Inc, Taiho Oncology Inc; Data Monitoring Committee: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck.
  
  Rita Nanda, MD
  Co-Director, Breast Medical Oncology
  Associate Professor of Medicine
  Section of Hematology/Oncology
  The University of Chicago
  Chicago, Illinois
  
  Advisory Committee: Celgene Corporation, Pfizer Inc, Puma Biotechnology Inc, Syndax Pharmaceuticals Inc; Contracted Research:Celgene Corporation, Genentech BioOncology, Merck.
  
  Sara Tolaney, MD, MPH
  Department of Medical Oncology
  Dana-Farber Cancer Institute
  Assistant Professor in Medicine
  Harvard Medical School
  Boston, Massachusetts 
  
  Contracted Research: Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Foundation Medicine, Lilly and Novartis.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: October 2017
  Expiration date: October 2018